Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript
Karyopharm Therapeutics Inc. recently discussed the results of its Phase III SENTRY trial involving Selinexor combined with Ruxolitinib for treating Myelofibrosis. The conference call featured key executives who provided insights into the trial outcomes and their implications for future treatments. This presentation was part of the American Society of Clinical Oncology (ASCO) conference.
- ▪Karyopharm Therapeutics Inc. presented the results of its Phase III SENTRY trial at the ASCO conference.
- ▪The trial evaluated the efficacy of Selinexor in combination with Ruxolitinib for patients with Myelofibrosis.
- ▪Key executives from Karyopharm participated in the conference call to discuss the trial findings.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4911160-karyopharm-therapeutics-inc-kpti-discusses-phase-iii-sentry-trial-results-of-selinexor-plus"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
